Multiple sclerosis therapeutics 2nd Edition by Richard Rudick, Jeffrey Cohen 1841842264 978-1841842264
Original price was: $50.00.$35.00Current price is: $35.00.
Multiple sclerosis therapeutics 2nd Edition by Richard A. Rudick, Jeffrey A. Cohen – Ebook PDF Instant Download/DeliveryISBN: 1841842264, 978-1841842264
Full download Multiple sclerosis therapeutics 2nd Edition after payment.
Product details:
ISBN-10 : 1841842264
ISBN-13 : 978-1841842264
Author: Richard A. Rudick, Jeffrey A. Cohen
This revised textbook examines the most important aspects of multiple sclerosis that impact on clinical trial design, on the development of new disease therapies, and, most importantly, on patient care. An international team of contributors discusses the clinical course of multiple sclerosis, its clinical heterogeneity, and the presence of subclinical disease activity which occurs during the early stages of the disease. There have been substantial advances in the field since the first edition was published in 1999. There are new chapters on functional imaging, the issues involved in long-term follow-up studies, cyclophosphamide, sex hormones and pregnancy-related factors, complementary and alternative treatments, management of cognitive impairment, treatment of pain, and rehabilitative approaches. Chapters on MS pathogenesis, imaging, the interferons, glatiramer acetate, mitoxantrone, IVIg, plasma exchange, stem cell transplantation, combination therapies, and newly-emerging treatments have been updated. This book is essential for any clinician who works with MS patients.
Multiple sclerosis therapeutics 2nd Table of contents:
1 Aspects of multiple sclerosis that relate to clinical trial design and treatment Jeffrey A Cohen and Richard A Rudick
2 Measures of neurologic impairment and disability in multiple sclerosis
3 Assessment of neuropsychological function in multiple sclerosis
4 Health-related quality of life assessment in multiple sclerosis
5 Magnetic resonance imaging in multiple sclerosis: an overview
6 Measures of gadolinium enhancement in multiple sclerosis
7 Measures of magnetization transfer in multiple sclerosis
8 Measures of T1 and T2 relaxation in multiple sclerosis Marianne AA van Walderveen and Frederick Barkhof
9 Measurement of central nervous system atrophy in multiple sclerosis Elizabeth Fisher and Richard A Rudick
10 Measures to quantify axonal damage in vivo based on magnetic resonance
11 Functional imaging in multiple sclerosis
12 Use of cost analyses to improve our understanding of the therapeutic trade- 251 offs for multiple sclerosis
13 Ethical considerations in multiple sclerosis clinical trials William Pryse-Phillips
14 The process of drug development and approval in the USA, the European 272 Union and Canada
15 Sponsors, monitoring committees and investigators: the investigator’s perspective
16 Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: 292
17 The failed clinical trial in multiple sclerosis
18 The challenge of long-term studies in multiple sclerosis: use of pooled data, 308 historical controls, and observational studies to determine efficacy John H
19 Emerging concepts of pathogenesis: relationship to MS therapies Jorge R Oksenberg, Sergio E Baranzini and Stephen L Hauser
People also search for Multiple sclerosis therapeutics 2nd:
frequency therapeutics multiple sclerosis
abata therapeutics multiple sclerosis
horizon therapeutics multiple sclerosis
therapeutics for multiple sclerosis symptoms
is ms the same as multiple sclerosis
Tags: Multiple sclerosis, therapeutics, Richard Rudick, Jeffrey Cohen